Josep-Maria Ribera , Olga Garc ıa, Buenaventura Buend ıa-Ure~ na, Maria-Jos e Terol, Ana Vicent, Ferran Vall-Llovera, Juan Bergua , Irene Garc ıa-Cadenas, Jordi Esteve , Jordi Ribera, Evelyn Acu~ naCruz, Pilar Herrera, Jesus-Maria Hern andez-Rivas, Pau Abrisqueta, Jos e Gonz alez-Campos , Carlos Rodr ıguez, Mariana Bastos-Oreiro, Eul alia Genesc a, Nerea Caminos, Maria-Paz Queipo de Llano, Ant onia Cladera, Juan-Manuel Sancho and on behalf of the Members of PETHEMA: Josep-Maria Ribera, Olga Garc ıa, Ferran Vall-Llovera, Juan Bergua, Irene Garc ıa-Cadenas, Jordi Esteve, Jordi Ribera, Evelyn Acu~ na-Cruz, Jesus-Maria Hern andez-Rivas, Jos e Gonz alez-Campos, Eul alia Genesc a, Maria-Paz Queipo de Llano, Ant onia Cladera Members of GELTAMO: Buenaventura Buend ıa-Ure~ na, Maria-Jos e Terol, Ana Vicent, Pilar Herrera, Pau Abrisqueta, Carlos Rodr ıguez, Mariana Bastos-Oreiro, Nerea Caminos, JuanManuel Sancho Groups Hematology Department, ICO-Hospital Germans Trias i Pujol, Josep Carreras Leukemia Research Institute (IJC), Universitat Aut onoma de Barcelona, Barcelona, Spain; Hematology Department, Hospital Universitario 12 de Octubre, Madrid, Spain; Hematology Department, Hospital Cl ınico, Valencia, Spain; Hematology Department, ICO-Hospital Joan XXIII, Tarragona, Spain; Hematology Department, Hospital M utua Terrassa, Terrassa, Spain; Hematology Department, Hospital San Pedro de Alc antara, C aceres, Spain; Hematology Department, Hospital de Sant Pau, Barcelona, Spain; Hematology Department, Hospital Cl ınic, Barcelona, Spain; Hematology Department, Hospital Universitario y Polit ecnico La Fe, Valencia, Spain; Hematology Department, Hospital Ram on y Cajal, Madrid, Spain; Hematology Department, Hospital Universitario de Salamanca, Salamanca, Spain; Hematology Department, Hospital Universitari Vall d’Hebron, Barcelona, Spain; Hematology Department, Hospital Universitario Virgen del Roc ıo, Sevilla, Spain; Hematology Department, Hospital Universitario de Gran Canaria Doctor Negr ın, Las Palmas de Gran Canaria, Spain; Hematology Department, Hospital Gregorio Mara~ n on, Instituto de Investigaci on Sanitaria Gregorio Mara~ n on, Madrid, Spain; Hematology Department, Hospital Universitario de Donostia, San Sebasti an, Spain; Hematology Department, Hospital Universitario Virgen de la Victoria, M alaga, Spain; Hematology Department, Hospital Universitari Son Ll atzer, Palma de Mallorca, Spain
[1]
Scott E. Smith,et al.
Burkitt Lymphoma International Prognostic Index.
,
2021,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2]
Scott E. Smith,et al.
Burkitt Lymphoma in the Modern Era: Real World Outcomes and Prognostication Across 30 US Cancer Centers.
,
2020,
Blood.
[3]
W. Wilson,et al.
Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma.
,
2020,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4]
P. Abrisqueta,et al.
Rituximab and Specific Therapy for Patients with Burkitt's Leukemia and Lymphoma. Results of the BURKIMAB14 Trial from the Spanish Pethema and Geltamo Groups in 80 Patients
,
2019,
Blood.
[5]
J. Esteve,et al.
Dose‐intensive chemotherapy including rituximab in Burkitt's leukemia or lymphoma regardless of human immunodeficiency virus infection status
,
2013,
Cancer.
[6]
Mario Corea,et al.
Hospital Verge de la Cinta
,
1995
.